← Back to Screener
Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM)
Price$4.26
Growth ScoreA
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-71.26%
Price vs S&P 500 (4W)-11.18%
VGM Score64.23
Market Capitalization$39.93M
All Metrics
Book Value / Share (Quarterly)$1.78
Cash Flow / Share (Quarterly)$-2.12
Price vs S&P 500 (YTD)-51.49%
Net Profit Margin (TTM)-9078.87%
EPS (TTM)$-8.72
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-8.72
EPS (Annual)$-7.97
ROI (Annual)-76.01%
Gross Margin (Annual)-641.58%
Cash / Share (Quarterly)$1.18
ROA (Last FY)-61.46%
Revenue Growth TTM (YoY)236.06%
EBITD / Share (TTM)$-4.94
ROE (5Y Avg)-75.83%
Operating Margin (TTM)-5052.26%
Cash Flow / Share (Annual)$-48.45
P/B Ratio4.14x
P/B Ratio (Quarterly)3.86x
Net Income / Employee (Annual)$-2,617,500
Net Interest Coverage (TTM)-1.13x
ROA (TTM)-188.70%
EPS Incl Extra (Annual)$-7.97
Current Ratio (Annual)2.28x
Quick Ratio (Quarterly)1.06x
3-Month Avg Trading Volume0.02M
52-Week Price Return-70.98%
Revenue / Employee (TTM)$16,600
Tangible BV / Share (Quarterly)$0.62
P/S Ratio (Annual)146.81x
Asset Turnover (Annual)0.00x
52-Week High$52.00
EPS Excl Extra (Annual)$-7.97
26-Week Price Return-63.34%
Quick Ratio (Annual)2.22x
13-Week Price Return21.43%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)1.07x
Enterprise Value$28.63M
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$19,500
Pretax Margin (Annual)-19353.53%
Cash / Share (Annual)$28.71
3-Month Return Std Dev213.69%
Net Income / Employee (TTM)$-2,617,500
ROE (Last FY)-77.29%
Net Interest Coverage (Annual)-1.13x
EPS Basic Excl Extra (Annual)$-7.97
Receivables Turnover (TTM)0.20x
Total Debt / Equity (Quarterly)0.27x
EPS Incl Extra (TTM)$-8.72
ROI (TTM)-316.78%
P/S Ratio (TTM)172.57x
Revenue / Share (Annual)$1.80
Price vs S&P 500 (52W)-95.34%
Year-to-Date Return-43.33%
5-Day Price Return-18.94%
EPS Normalized (Annual)$-7.97
ROA (5Y Avg)-64.82%
Net Profit Margin (Annual)-19353.53%
Month-to-Date Return-37.37%
EBITD / Share (Annual)$-4.93
Operating Margin (Annual)-13644.50%
ROI (5Y Avg)-74.32%
EPS Basic Excl Extra (TTM)$-8.72
P/TBV (Quarterly)11.09x
Inventory Turnover (TTM)4.70x
Pretax Margin (TTM)-9078.87%
Price vs S&P 500 (13W)13.17%
Beta4.57x
Revenue / Share (TTM)$0.02
ROE (TTM)-417.59%
52-Week Low$2.85
gGradeA
mGradeD
vgmGradeB
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares | — | A | D | $4.26 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Quantum BioPharma is a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Its lead asset, Lucid-MS, is a patented therapeutic in preclinical development designed to prevent and reverse myelin degradation in multiple sclerosis. The company also maintains a portfolio of property-backed loans through a wholly owned subsidiary.